 1. Radiotherapy except for palliative reasons, endocrine therapy, immunotherapy or chemotherapy during the previous four weeks six weeks for nitrosoureas, Mitomycin-C and 4 weeks for investigational medicinal products before treatment, except for hormonal therapy with luteinizing hormone-releasing hormone LHRH analogues for medical castration in patients with castrate resistant prostate cancer, which are permitted, and bisphosphonates or RANK ligand antagonists that are permitted for the management of bone metastases. Palliative radiotherapy is acceptable if given for bony metastases as long as these are not indicative of disease progression. Study drug must be stopped 3 days before radiotherapy and restarted within 28 days, as long as bone marrow function has returned to normal. 